The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy

PharmacoEconomics

Volumn 24, Issue 6, 2006, Pages 549-558

  Carides, George W ^a   Shahinfar, Shahnaz ^a   Dasbach, Erik J ^a   Keane, William F ^a   Gerth, William C ^a   Alexander, Charles M ^a   Herman, William H ^b   Brenner, Barry M ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOSARTAN; PLACEBO;

ARTICLE; CONTROLLED STUDY; DRUG COST; FEMALE; HEALTH CARE SYSTEM; HOSPITAL COST; HUMAN; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG COSTS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; MIDDLE AGED; UNITED STATES;

EID: 33745061623     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624060-00003     Document Type: Article

References (21)

1. Sandoz MS, Ess SM, Keusch GW, et al. Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001. Swiss Med Wkly 2004 Aug 7; 134 (31-32): 448-58
2. US Renal Data System. USRDS 2002 annual data report: atlas of end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002
3. Van Dijk PC, Jager KJ, Stengel B, et al. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 2005 Apr; 67 (4): 1489-99
4. Bommer J. Prevalence and socio-economic aspects of chronic kidney disease. Nephrol Dial Transplant 2002; 17 Suppl. 11: 8-12
5. US Renal Data System. USRDS 2000 annual data report. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2000 Jun: 251
6. Gordios A, Scuffham P, Shearer A, et al. The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications 2004 Jan-Feb; 18 (1): 18-26
7. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9
8. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25: S33-49
9. Herman WH, Shahinfar S, Carides GW, et al. Losartan reduces the costs associated with diabetic end-stage renal disease. Diabetes Care 2003; 26 (3): 683-7
10. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997 Apr 30; 16 (8): 901-10
11. Lawless JF. Statistical models and methods for lifetime data. New York: Wiley, 1982
12. Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov EBN, Csaki F, editors. 2nd International Symposium of Information Theory and Control. Budapest: Akademia Kiado, 1973: 267-81
13. Wolfe RA, Hirth RA, Port FK, et al. Mortality and costs in the first year of dialysis: a comparison between hemodialysis (HD) and peritoneal dialysis (PD) [abstract]. J Am Soc Nephrol 1998; 9: 241A
14. Manninen DL, Dong FB, Dasbach EJ, et al. The longitudinal cost of end-stage renal disease in persons with diabetes in the United States. J Med Econ 2004; 7: 41-51
15. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall, 1993
16. Gerth WC, Remuzzi G, Viberti G, et al. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. Kidney Int 2002 Dec; 62 Suppl. 82: 68-72
17. Rodby RA, et al. The cost effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther 2003 Jul; 25 (7): 2102-19
18. US Department of Health and Human Services. Healthy People 2010. 2nd ed. With understanding and improving health and objectives for improving health. 2 vols. Washington, DC: US Government Printing Office, 2000 Nov
19. NHANES III Third National Health and Nutrition Examination Survey, 1988-1994. Hyattsville (MD): National Center for Health Statistics [online]. Available from URL: http://www.cdc.gov/nchs/products/elec_prods/subject/nhanes3. htm [Accessed 2006 Feb]
20. Joyce AT, Iacoviello JM, Nag S, et al. End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care 2005; 27: 2829-35
21. Murray L, editor. Physician's desk reference. 60th ed. Montvale (NJ): Thomson PDR, 2006: 1916